Allos Therapeutics News

Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any applicable withholding taxes, plus one Contingent ... (more)

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Spectrum Pharmaceuticals, Inc.

BUYINS.NET: Market Maker Surveillance Report. CPWM, THC, ALTH, CSCO, MSFT, F, Bullishly Biased Price Friction For Wednesday, May 9th 2012 BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday.

's stock had its "outperform" rating restated by Zacks in a research report issued to clients and investors on Monday.

SPPI -0.8% ALTH +0% BIIB -2.47% AGN -0.79% BMY -0.39% GSK -1.71% ENDP -1.17% BDSI -1.3% The National Cancer Institute estimates in its Cancer Statistics Review that over 1.5 million individuals will be diagnosed with cancer in 2012.